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Individuals with Type 1 diabetes (T1D) are often exposed to recurrent episodes of hypoglycaemia. This
reduces hormonal and behavioural responses that normally counteract low glucose in order to maintain
glucose homeostasis, with altered responsiveness of glucose sensing hypothalamic neurons implicated.
Although the molecular mechanisms are unknown, pharmacological studies implicate hypothalamic
ATP-sensitive potassium channel (KATP) activity, with KATP openers (KCOs) amplifying, through cell hy-
perpolarization, the response to hypoglycaemia. Although initial ﬁndings, using acute hypothalamic KCO
delivery, in rats were promising, chronic exposure to the KCO NN414 worsened the responses to sub-
sequent hypoglycaemic challenge. To investigate this further we used GT1-7 cells to explore how NN414
affected glucose-sensing behaviour, the metabolic response of cells to hypoglycaemia and KATP activity.
GT1-7 cells exposed to 3 or 24 h NN414 exhibited an attenuated hyperpolarization to subsequent
hypoglycaemic challenge or NN414, which correlated with diminished KATP activity. The reduced
sensitivity to hypoglycaemia was apparent 24 h after NN414 removal, even though intrinsic KATP activity
recovered. The NN414-modiﬁed glucose responsiveness was not associated with adaptations in glucose
uptake, metabolism or oxidation. KATP inactivation by NN414 was prevented by the concurrent presence
of tolbutamide, which maintains KATP closure. Single channel recordings indicate that NN414 alters KATP
intrinsic gating inducing a stable closed or inactivated state. These data indicate that exposure of hy-
pothalamic glucose sensing cells to chronic NN414 drives a sustained conformational change to KATP,
probably by binding to SUR1, that results in loss of channel sensitivity to intrinsic metabolic factors such
as MgADP and small molecule agonists.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).DMEM, Dulbecco's modiﬁed
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Individuals with Type 1 Diabetes (T1D) often experience
repeated episodes of hypoglycaemia as a consequence of exoge-
nous insulin therapy. This recurring exposure to hypoglycaemia
results in a reduction in the magnitude and altered threshold of
symptomatic, hormonal and behavioural counterregulatory re-
sponses (CRR) to subsequent hypoglycaemia: a syndrome called
impaired hypoglycaemia awareness (Adamson et al., 1984; Davis
and Shamoon, 1991; Heller and Cryer, 1991; Inouye et al., 2002;
Jacobson et al., 2006; Sanders et al., 2006). This response to
recurrent hypoglycaemia can also be elicited in rodent models,
leading to the identiﬁcation of altered glucose sensitivity of hypo-
thalamic neurons as an important contributory mechanism
(Alquier et al., 2007; Dunn-Meynell et al., 2002; Fioramonti et al.,
2013; Kang et al., 2008; McCrimmon et al., 2005, 2006; Sanderse under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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lished that the brain, in particular certain regions of the hypothal-
amus, regulates the physiological responses to hypoglycaemia in an
effort to maintain whole body glucose homeostasis (Borg et al.,
1994, 1995, 1997). Unfortunately, there are no effective treat-
ments for defective CRR in type 1 diabetes other than the strict
avoidance of hypoglycaemia that has only been achieved in inten-
sive clinical trials involving small numbers of participants. There-
fore, there is an urgent requirement to identify alternative
therapies and/or adjunct molecules that act centrally to prevent, or
restore, defective CRR, but also to deﬁne their biological and
pharmacological mechanisms.
Central glucose sensing occurs in specialised neurons, many of
which express the canonical proteins associated with pancreatic
beta cell glucose sensing: glucokinase and ATP-sensitive potassium
(KATP) channels (Ashford et al., 1990a, 1990b; Beall et al., 2012;
Claret et al., 2007; Kang et al., 2004, 2006; Tarasov et al., 2004).
Furthermore, the increased opening of hypothalamic KATP channels
in glucose sensing neurons (resulting in neuronal hyperpolar-
ization and inhibition of ﬁring), in response to a fall in circulating
glucose levels, is required to initiate an appropriate CRR to hypo-
glycaemia (Miki et al., 2001). In vivo rodent studies have shown that
direct microinjection of the KATP channel openers (KCOs), diazoxide
or NN414 into the ventromedial hypothalamus (VMH), immedi-
ately prior to hypoglycaemia ampliﬁes adrenaline and glucagon
secretion during hyperinsulinaemic-hypoglycaemic clamp studies
(McCrimmon et al., 2005). Additionally, VMH microinjection of
diazoxide is also able to amplify the CRR following recurrent
hypoglycaemia, in a rodent model of defective CRR (McCrimmon
et al., 2005). Conversely, intracerebroventricular (ICV) infusion or
VMH microinjection of selective KATP inhibitors (which depolarize
and increase neuronal ﬁring), such as the sulphonylureas, gliben-
clamide or tolbutamide, attenuates the CRR during both systemic
hypoglycaemia and cerebral glucopenia, resulting in blunted
glucagon and adrenaline secretion (Evans et al., 2004).
Consequently, it has been reasoned that agents, which act
selectively to increase the opening of hypothalamic KATP channels,
could be useful ampliﬁers of glucose counter-regulatory responses.
KATP channels are composed of one of the two members of the
inward-rectiﬁer Kþ channel family, KIR6 and one of the three forms
of the sulphonylurea receptor (SUR) subunit family. KATP channels
that sub-serve glucose sensing in hypothalamic neurons express
the SUR1 subunit (Ashford et al., 1990a; Dunn-Meynell et al., 1998;
Kang et al., 2004; Lee et al., 1999; McCrimmon et al., 2005). While
diazoxide is capable of activating both SUR2 and SUR1 subtypes of
KATP channels, NN414 is a SUR1 selective agonist and has been
shown to be a more potent activator than diazoxide of Kir6.2-SUR1
containing KATP channels (Dabrowski et al., 2003). Initial studies on
rodents demonstrated encouraging results, with acute systemic
delivery of NN414 resulting in an ampliﬁed CRR to hypoglycaemia,
which was prevented by local delivery of glibenclamide to the VMH
(Fan et al., 2008; McCrimmon et al., 2005). Unexpectedly, chronic
ICV infusion of NN414 to rats during antecedent hypoglycaemia
induced a larger depression of the CRR to subsequent hypo-
glycaemic challenge (Beall et al., 2013). Furthermore, using GT1-7
neurons, an in vitro model of hypothalamic glucose sensing neu-
rons that expresses Kir6.2-SUR1 containing KATP channels (Beall
et al., 2012), it was demonstrated that chronic exposure to NN414
or diazoxide profoundly impaired the up-regulation of KATP channel
activity in response to the removal of intracellular ATP (Beall et al.,
2013). Such an inactivation of hypothalamic KATP channels in vivo by
chronic NN414 might explain the reduced CRR response to hypo-
glycaemia observed in rats. Consequently, we hypothesised that
chronic hypothalamic KATP opening by KCOs may alter cellular
metabolism and nucleotide levels and/or affect KATP gating directlyresulting in maintained closure channel and diminished hypo-
glycaemic sensing.
To investigate this phenomenon further we used GT1-7 neurons
to determine the consequence of shorter-term exposure to KATP
channel activators on glucose sensing and to examine whether one
or more of these mechanisms underlie agonist-driven KATP channel
inactivation.
2. Materials and methods
2.1. Cell culture
Mouse hypothalamic GT1-7 cells (Pamela Mellon, San Diego,
California, USA) (Mellon et al., 1990) were maintained in Dulbecco's
modiﬁed Eagle medium (DMEM; Gibco, Invitrogen, Paisley, UK)
containing 2.5 mM glucose with 10% fetal bovine serum (FBS; PAA
Laboratories, Yeovil, UK), as previously described (Beall et al., 2012).
For continuous exposure to NN414 (5 mM; Novo Nordisk, Copen-
hagen, Denmark), diazoxide (250 mM; Sigma-Aldrich) or tolbuta-
mide (200 mM; Sigma-Aldrich), cells were grown on poly-l-lysine-
coated glass coverslips at ~10e20% conﬂuence. Vehicle-treated
cells received 2 ml 0.1 M NaOH (NN414) or 0.1% DMSO (diazoxide,
tolbutamide), with pH maintained at 7.4. In all experiments where
GT1-7 cells underwent NN414 or vehicle challenge prior to elec-
trophysiological or metabolic assessment, cells were superfused or
washed thoroughly with normal saline (2.5 mM glucose) before
measurements initiated.
2.2. Electrophysiology
All electrophysiology experiments were conducted using an
Axopatch 200B ampliﬁer (Axon Instruments, Foster City, CA, USA)
and analysed using PCLAMP7 software (Axon Instruments). GT1-
7 cells were superfused at room temperature (22e25 C) with
normal saline (in mM): 135 NaCl, 5 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES,
0.5 or 2.5 glucose (pH 7.4). Membrane potentials were recorded
using perforated-patch or whole-cell current-clamp conﬁgurations,
and membrane currents recorded using the whole-cell voltage
clamp mode. In whole-cell experiments, cells were maintained in
current-clamp mode to monitor resting membrane potential prior
to a voltage clamp protocol to obtain currentevoltage relations;
whereby the cell was clamped at a holding potential of70mV and
voltage steps ranging from 90 mV to þ30 mV were elicited for a
duration of 400 ms at intervals of 20s (net range 160 to 40 mV).
Recording electrodes were pulled from thin borosilicate glass (open
tip resistance of 3e5 MU) and ﬁlled with an intracellular solution
containing (mM): 140 KCl, 5 MgCl2, 3.8 CaCl2, 10 EGTA, 10 HEPES,
pH 7.2 (free [Ca2þ] of 100 nM). Whole cell macroscopic currents
were examined immediately (~1e2 min) after the cell membrane
was ruptured (control) and after the cell had been dialysed
(~12e15 min) with 0 ATP (by which time KATP channels were
maximally open, termed run-up). Current- and voltage-clamp data
were collected and analysed as described previously (Beall et al.,
2010). For perforated-patch recordings, the electrode solution
contained (in mM): 140 KCl, 5 MgCl2, 3.8 CaCl2, 10 HEPES, 10 EGTA
(pH 7.2) and 25e40 mg/ml amphotericin B (Sigma-Aldrich).
Following attainment of the perforated patch recording conﬁgu-
ration, a minimum of 10 min of stable recording was collected in
normal saline (2.5 mM glucose) before switching to a solution
containing 0.5 mM glucose with or without tolbutamide (200 mM)
(Sigma-Aldrich) and/or NN414 (5 mM) or diazoxide (250 mM).
For single channel recordings, patches of cell membrane were
isolated and maintained in the inside-out conﬁguration. Recording
electrodes were pulled from thinwalled borosilicate glass (open tip
resistance of 10e12 MU) and ﬁlled with an intracellular solution
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intracellular aspect of the membrane was exposed to a bathing
solution containing (mM): 140 KCl, 1 MgCl2, 2.7 CaCl2, 10 EGTA, 10
HEPES, pH 7.2 (free [Ca2þ] of 100 nM).When 100 mMATPwas added
to the bath, the [Mg2þ] was raised to 1.1 mM to compensate for the
Mg2þ chelation by ATP and maintain a free [Mg2þ] of 65 nM. KATP
channel activity was recorded for no longer than 15 min in order to
avoid excessive channel run down, as previously reported (Larsson
et al., 1993). 5 mMNN414, 200 mMMgADP or 100 mg/ml Trypsinwas
acutely applied to patches in the presence of 100 mM ATP. The
average channel activity in a patch was deﬁned as N.Po, where
N ¼ the number of functional channels in the patch and Po ¼ the
open state probability, which was determined by measuring the
total time spent at each unitary current level and expressed as a
proportion of the total time of the segment of recording (90e120 s)
that was analysed. N.Po was calculated using the PCLAMP7 soft-
ware which incorporates a 50% threshold parameter in order to
detect single channel events which are >50% of a predetermined
unitary current amplitude.
2.3. Glucose uptake
GT1-7 cells were exposed to NN414 (5 mM) or vehicle for 24 h
prior to uptake analysis. Cells werewashed in Hepes Buffered saline
(HBS (in mM): 140 NaCl, 20 Hepes, 5 KCl, 2.5 MgSO4, 1 CaCl2, 2.5
Glucose, pH 7.4) and serum-starved (1 h) prior to incubation
(12 min) with 10 mM 2-deoxy-D-[3H]glucose (2DG; 24.4 kBq/ml;
PerkinElmer, Cambridge UK) and 0, 0.1, 0.5 or 2.5 mM glucose at
20 C. Non-speciﬁc uptake was determined using 10 mM cytocha-
lasin B (Sigma-Aldrich). Following wash and cell lysis, cell-
associated radioactivity was measured (Beckman LS60000IC scin-
tillation counter; Beckman, High Wycombe, UK) and protein con-
tent quantiﬁed by Bradford reagent. Each uptake measurement was
made up of 10 replicates.
2.4. Glucose oxidation
GT1-7 cells were pre-exposed to NN414 (5 mM) or vehicle for
24 h and following wash with HEPES buffered saline (HBS) were
incubated for 4 h with 74 kBq/ml D-[Ue14C]glucose (PerkinElmer)
and 0.1, 0.5 or 2.5 mM glucose in HBS at 37 C. Subsequently, the
media were transferred to 15 ml tubes and the 14CO2 released using
200 ml 60% perchloric acid and trapped by Whatman (GF/B) ﬁlter
paper discs pre-soaked in 1 M KOH. Radioactivity was quantiﬁed by
liquid-scintillation counting.
2.5. Hexokinase assay
GT1-7 cells were treatedwithNN414 (5 mM) or vehicle for 24 h in
2.5 mM glucose, then washed with ice-cold HBS followed by ice-
cold Tris base, TES (N-tris(hydroxylmethyl)methyl-1-L-amino-
ethine sulphonic acid, glacial acetic acid (TTA) buffer before un-
dergoing three freeze/thaw cycles, spun at 12000 rpm at 4 C for
10 min followed by lysis. The hexokinase assay reaction mixture
contained (in mM): 39 TTA buffer (pH 7.6), 7.8 MgCl2, 1.1 b-NADP,
0.74 ATP, 2.5 U glucose-4-phosphate dehydrogenase, 0e100 glucose
plus 5e10 mg of lysate, with the ATP added last to initiate the re-
action. Absorbance of b-NADPH was measured at 355 nm at 30 C.
2.6. Cellular respiration
GT1-7 cells were seeded (30,000 cells/well) in XF 24-well cul-
ture microplates (Seahorse Bioscience, Copenhagen, Denmark)
with NN414 (5 mM) or vehicle for 24 h in 2.5mM glucose. Cells were
then washed in serum-free media (2.5 mM glucose) for 1 h prior tomeasurements being taken. Baseline recordings were taken to
ensure a steady respiratory rate prior to injection of mitochondrial
inhibitors for analysis of mitochondrial function.
2.7. Nucleotide assay
GT1-7 cell intracellular ATP/ADP ratios were determined by
bioluminescence assay (ab65313, Abcam, Cambridge, UK). Cells
were seeded (1000 cells/well) with NN414 (5 mM) or vehicle for
24 h in 2.5 mM glucose. Following cell lysis, luminescence intensity
was determined by luminescence microplate reader (CentroPro LB
962 Luminometer, Berthold Technologies, Bad Wildbad, Germany).
2.8. Statistical analysis
One-way ANOVA, with a post-hoc Bonferroni test, was used to
determine statistical differences between 3 or more groups, such as
in the electrophysiological recordings. All other data sets were
analysed using an unpaired Student's t-test (Graphpad, Prism 5
software). Data are presented as mean ± SEM. Statistical signiﬁ-
cance was accepted at the 95% conﬁdence value with a P value of
less than 0.05. Signiﬁcance was allocated to the following P values:
* <0.05; **< 0.01 and ***<0.001.
3. Results
3.1. Chronic exposure of GT1-7 cells to NN414 blunts hypoglycaemia
detection
As shown previously (Beall et al., 2012), perforated patch re-
cordings from GT1-7 cells in 2.5 mM glucose demonstrated spon-
taneous ﬁring activity with a mean resting membrane potential
of 50.7 ± 2.7 mV (n ¼ 4), and following challenge with 0.5 mM
glucose these neurons responded by hyperpolarization
to 65.5 ± 1.9 mV with cessation of ﬁring, effects reversible on
return to 2.5 mM glucose-containing solution (52.2 ± 2.6 mV; Fig
1A). In the continued presence of 2.5mMglucose, application of the
SUR1-selective KATP activator, NN414 (5 mM) also rapidly hyper-
polarized these neurons, to74.0 ± 2.0mV, and inhibited ﬁring (Fig
1A), an action reversible on washout of drug (not shown). When
GT1-7 cells were exposed to 5 mMNN414 for 24 h, after the removal
of drug (recordings initiated within 30 min) we observed no dif-
ference in the mean resting membrane potential (47.2 ± 2.2 mV;
n ¼ 6) or excitability of GT1-7 cells in 2.5 mM glucose compared to
control or vehicle treated cells (Fig. 1B). However, these antecedent
NN414-exposed cells no longer responded by hyperpolarization
(Fig. 1B) to challenge with 0.5 mM glucose (NN414
DVm ¼ 1.7 ± 0.8 mV; Vehicle, DVm ¼ 14.8 ± 2.8 mV; p < 0.001,
n ¼ 4e6; Fig. 1C) and exhibited an attenuated response to further
challenge with NN414, with the membrane potential hyper-
polarizing from 45.0 ± 2.6 mV to 59.2 ± 2.8 mV (NN414,
DVm ¼ 13.8 ± 1.8 mV; vehicle, DVm ¼ 24.2 ± 2.6 mV; p < 0.005,
n¼ 6e9). This outcome is not surprising as chronic (24 h or longer)
treatment of GT1-7 cells with NN414 has been demonstrated to
push KATP channels into a stable inactivated state (Beall et al., 2013).
Next we examined whether a shorter-term exposure of GT1-
7 cells to NN414 replicated this action on KATP conductance and
resulted in attenuated glucose sensing. Consequently, we tested the
effects of antecedent 3-h NN414 or vehicle incubation on GT1-7 cell
response to lowered glucose. In agreement with longer-term
exposure, following washout of NN414, GT1-7 cell membrane po-
tential and ﬁring rates were comparable between groups in 2.5 mM
glucose-containing solution (Fig. 1D,E). However, on challengewith
0.5 mM glucose, NN414-treated cells once again displayed a
blunted hyperpolarization response to a low glucose challenge
Fig. 1. Chronic NN414 treatment attenuates the hyperpolarization and conductance increase induced by low glucose and acute NN414 in GT1-7 cells. (A, B) Representative
perforated-patch current clamp recordings from GT1-7 cells exposed to vehicle (A) or 5 mMNN414 (B) for 24-h. Acute application of 0.5 mM glucose to vehicle-treated cells results in
membrane hyperpolarization and cessation of action potential activity, which is reversible on return to 2.5 mM glucose. In contrast, cells previously exposed to NN414 exhibit no
response to 0.5 mM glucose. Subsequent acute challenge with 5 mM NN414 causes hyperpolarization in both cases, although this response is attenuated in the antecedent NN414-
treated cells. Bar graphs showing mean values for membrane potentials in 2.5 mM (white bars), 0.5 mM (black bars) glucose and 2.5 mM glucose þ NN414 (grey bars) for cells
exposed to vehicle (A; n ¼ 4) of NN414 (B; n ¼ 6). (C) Bar graph showing the mean change in membrane potential of cells exposed chronically to vehicle or NN414 (24-h) on
challenge with 0.5 mM glucose. (D, E) Representative perforated-patch current clamp recordings from GT1-7 cells exposed to vehicle (D) or NN414 (E) for 3-h. As observed for the
24-h exposure, antecedent treatment with NN414 for 3-h also blunted responses to acute 0.5 mM glucose and NN414 challenge. (F) Bar graph showing the mean change in
membrane potential of cells exposed chronically to vehicle or NN414 (3-h) on challenge with 0.5 mM glucose. (G) Conductance density for vehicle-treated (white bar) vs 3-h NN414-
treated (black bar) cells (n ¼ 5). (H) Conductance density for vehicle-treated (white bar) vs 3-h 250 mM diazoxide-treated (black bar) cells (n ¼ 5). Values are mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001.
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p < 0.001, n ¼ 5; Fig. 1F) along with an attenuated response to
acutely applied NN414 (NN414, DVm ¼ 13.8 ± 2.9 mV; vehicle,
DVm ¼ 27.0 ± 3.8 mV; p < 0.01, n ¼ 5). Consistent with a reduced
KATP-responsiveness to either metabolic challenge or direct agonist
application, whole-cell voltage clamp experiments on GT1-7 cells
exposed to antecedent 3-h NN414 revealed a signiﬁcantly reduced
maximal KATP current compared to vehicle-treated cells (Fig. 1G). Inaddition, short-term exposure of cells to diazoxide (n ¼ 5) pro-
duced a similar inhibition of maximal KATP conductance (Fig. 1H).
3.2. Chronic exposure to NN414 blunts hypoglycaemia detection in
GT1-7 cells even following a 24hr wash out period
We have previously shown that the chronic NN414 mediated
suppression of KATP conductance in GT1-7 cells was completely
E. Haythorne et al. / Neuropharmacology 111 (2016) 212e222216reversible after 24 h following washout of the drug (Beall et al.,
2013). This recovery of KATP conductance was also observed 24 h
after washout from a 3-h exposure to NN414 and was indistin-
guishable from vehicle-treated cells (Fig. 2AeC). In addition, GT1-
7 cells with antecedent vehicle exposure and 24-h washout
exhibited the typical response to lowered glucose and acute NN414
challenge (Fig. 2D, E). However, there remained a signiﬁcant
reduction in responsiveness to hypoglycaemia challenge in the
antecedent NN414 exposed cells (Vehicle, DVm ¼ 14.3 ± 1.4 mV;
NN414, DVm ¼ 3.8 ± 1.7 mV, n ¼ 4e6; Fig. 2F), and a diminished
response to acute NN414 challenge (NN414,DVm¼16.9 ± 1.5mV;
vehicle, DVm ¼ 23.4 ± 1.6 mV; p < 0.005, n ¼ 9e10; Fig. 2D, E).
Consequently, although the KATP channel availability (as deﬁned in
whole-cell conditions following washout of intracellular ATP) is
recoverable 24 h after washout of NN414, the channel appears to be
much less available for opening by metabolic stimulus and so GT1-
7 cells continue to display impaired glucose sensing.
3.3. Chronic NN414 exposure does not alter the GT1-7 metabolic
response to hypoglycaemia
To dissect the mechanism behind the loss of glucose sensing
following chronic NN414 exposure, we ﬁrst investigated whetherFig. 2. The NN414-associated suppression of KATP current is readily reversible but the resp
Representative current-clamp recordings of membrane potential and voltage-clamp record
NN414 (5 mM; B) and following washout. Voltage-clamp currents are shown immediately
tolbutamide. (C) Conductance density for vehicle-treated (white bar) and NN414-treated (b
from GT1-7 cells exposed to vehicle (D) or 5 mM NN414 (E) for 3-h followed by washout. The
antecedent NN414-treated vs vehicle-treated cells. (F) Bar graph showing the mean chang
exposure to vehicle or NN414 (3-h) followed by washout. (n ¼ 6). Values are mean ± SEMthe metabolic responsiveness of GT1-7 cells to hypoglycaemia was
altered. We chose 24-h continuous NN414 as this duration of
agonist exposure ensured the most robust attenuation of glucose
sensing. The hypothesis tested was that chronic NN414 exposure
caused increased glucose uptake and/or more efﬁcient metabolism,
generating increased levels of ATP and so maintaining KATP closure
during subsequent hypoglycaemic challenges. However, we could
not detect any alteration in glucose uptake (Fig 3A) or glucose
oxidation and incorporation (Fig. 3B,C) between chronic NN414-
treated cells compared to vehicle controls, under physiological
euglycaemic (2.5 mM) or hypoglycaemic (0.1 and 0.5 mM) condi-
tions. Additionally, we did not observe any signiﬁcant difference in
hexokinase activity between NN414- and vehicle-treated cells (Fig
3D). To examine whether NN414 exposure resulted in altered
mitochondrial oxidative metabolism and cellular ATP production
we examined the real-time oxygen consumption rate (OCR) of
NN414- and vehicle-treated GT1-7 cells. The basal OCR was unal-
tered by NN414 in GT1-7 cells (Fig 3E). In a further examination
(Fig. 3FeK) of mitochondrial efﬁciency we utilised a modiﬁed
Mitochondrial Stress Test (Seahorse Bioscience). Thus ATP synthase
was inhibited by the addition of oligomycin to measure the pro-
portion of mitochondrial respiration dedicated to ATP production,
followed by assessment of mitochondrial leak (addition of rotenoneonse to low glucose and acute NN414 remains blunted, following drug washout. (A,B)
ings of currents from GT1-7 cells after 3-h treatment in control (vehicle-treated; A) or
after rupture, following run-up (ATP washed from cell) and after addition of 200 mM
lack bar) cells (n ¼ 6). (D, E) Representative perforated-patch current clamp recordings
hyperpolarizing responses to low (0.5 mM) glucose and acute NN414 are blunted in the
e in membrane potential on challenge with 0.5 mM glucose of cells with antecedent
. **p < 0.01.
Fig. 3. Chronic NN414 exposure does not alter glucose uptake and oxidation, mitochondrial function or nucleotide ratios in GT1-7 cells. (AeC) 2-deoxyglucose (2DG) uptake (A;
n ¼ 4), [14C]-glucose oxidation (B; n ¼ 3) and total [14C]-glucose incorporation (C; n ¼ 3) in 24 h vehicle- and NN414-treated GT1-7 cells, measured in 0.1, 0.5 and 2.5 mM glucose.
(D) Activity of hexokinase as a function of glucose concentration in GT1-7 cells following 24-h exposure to vehicle (,) or NN414 (C). The curved lines (vehicle, solid; NN414,
broken) represent lines of best ﬁt to the data points (n ¼ 4 determinations per point). (E) Oxygen consumption rate (OCR) of 24-h vehicle- and NN414-treated GT1-7 cells. (F)
Mitochondrial stress temporal proﬁle for 24-h vehicle- (,) and NN414-treated (C) GT1-7 cells showing the effects of the percentage change in normalized OCR of the sequential
addition of 1 mM oligomycin and 2 mM rotenone and antimycin A (n ¼ 7). (GeI) 24-h NN414 exposure had no effect on ATP-linked OCR (G), or on the OCR required to maintain the
mitochondrial leak (H) or the non-mitochondrial OCR (I) compared to vehicle-treated cells (n ¼ 7). (J) Temporal proﬁle showing the normalized baseline OCR for vehicle- (,) and
NN414-treated (C) cells and the maximum OCR (reserve capacity) attained following addition of 0.2 mM carboyl cyanide-triﬂuoromethoxyphenylhydrazone (FCCP). (K) 24 h NN414
exposure had no effect on the percentage OCR increase following FCCP addition compared to vehicle-treated cells (n ¼ 4). (L) the ATP-ADP ratio of GT1-7 cells was unchanged
following 24 h NN414 exposure, compared to vehicle controls (n ¼ 9). Values are mean ± SEM.
E. Haythorne et al. / Neuropharmacology 111 (2016) 212e222 217and antimycin A) and non-mitochondrial OCR, with no difference
detected in any of these parameters (Fig. 3FeI). Furthermore the
cellular reserve (“spare respiratory”) capacity of GT1-7 cells, as
determined by the addition of the proton ionophore, carbonyl cy-
anide-p-triﬂuoromethoxyphenylhydrazone (FCCP), to induce
maximal respiration, was also unaffected by previous exposure to
NN414 (Fig. 3J,K). Finally we measured the ATP/ADP ratio and, in
agreement with the results above, NN414 exposure produced nochange in this ratio (Fig. 3L). In summary, we detected no adapta-
tions in glucose metabolism or mitochondrial function, which
would help explain the attenuated glucose sensing following
chronic NN414. These results, in conjunction with the ﬁnding that
direct activators of KATP exhibit reduced efﬁcacy following NN414
washout (even after recovery of KATP conductance in whole-cell
recordings), suggested that alterations to the KATP channel itself
may be responsible.
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required for NN414 induced KATP inactivation
Next we investigated the possibility that the induction of pro-
longed cell hyperpolarization resulted in a stable “inactivated”
conformation of the KATP channel. To test this we increased the
extracellular concentration of Kþ to 13.5 mM in order to
chemically-clamp the cell at resting membrane potential but still
allow KATP channel opening by addition of NN414 without the
attendant hyperpolarization, as shown in perforated-patch re-
cordings from GT1-7 cells following acute exposure to NN414 (Fig
4A). Under chemical-clamp, we tested the effect of a 24-h expo-
sure of GT1-7 cells to NN414 or vehicle on the subsequent KATP
conductance measured by whole-cell voltage clamp. The maximal
conductance values determined from these cells following washout
of ATP showed that chronic exposure to NN414 signiﬁcantly
attenuated the whole-cell KATP current and maximum conductance
(Fig. 4BeD) in a manner identical to that observed for cells un-
dergoing hyperpolarization. A similar outcome was also obtained
with a shortened (3-h) exposure to NN414 in the presence of
13.5mMKþ solution (Fig 4E). Consequently, wewent on to examine
whether the KATP inactivating effect of chronic NN414 exposurewas
dependent on the ability of the KATP channel to open. To effect
maintained channel closure, GT1-7 cells were exposed to the KATP
channel inhibitor, tolbutamide (200 mM) and subsequentlyFig. 4. Chemical-clamp of cell membrane potential does not prevent chronic NN414 from re
of a GT1-7 cell demonstrating that acute NN414 application does not hyperpolarize the m
sentative whole-cell current-clamp recordings of membrane potential and voltage-clamp re
7 cells (C). (D) Pooled conductance density at run-up from 24-h KCl þ vehicle-vs 24-h
KCl þ vehicle-treated vs 3-h KCl þ NN414-treated (black bar) cells (n ¼ 11). Values are mechallenged with acute NN414, thus demonstrating prevention of
the hyperpolarizing response to the KATP activator (Fig 5A). For
chronic NN414 treatment, tolbutamide was present 1 h prior to
NN414 addition and continuous for the 24-h NN414 incubation
period, with appropriate vehicle controls. Subsequent whole-cell
current- and voltage-clamp recordings demonstrated that, in the
presence of tolbutamide þ NN414, the maximal cell conductance
following removal of the drugs was unchanged compared to their
vehicle controls (Fig. 5BeD), suggesting that NN414 is required to
bind to the channel complex and open KATP for inactivation to
occur.
3.5. Chronic NN414 exposure induces a refractory state for neuronal
KATP channels
Although the availability of KATP to activate maximally is
severely attenuated following continuous NN414 exposure, mRNA
for the channel subunits KIR6.2 (Kcnj11) and SUR1 (Abcc8) or the
protein levels of the fully assembled channel complex at the plasma
membrane were unchanged under these conditions (Beall et al.,
2013). Therefore, we performed single channel recordings on iso-
lated inside-out membrane patches in order to determine if ad-
aptations were occurring in the intrinsic activity of the KATP channel
following prolonged NN414 exposure that contribute to the
changes observed in glucose-sensing and subsequent KATP agonistducing KATP conductance. (A) Representative perforated-patch current clamp recording
embrane potential in the presence of high extracellular (13.5 mM) KCl. (B, C) Repre-
cordings of currents from 24-h KCl þ vehicle- (B) and 24-h KCl þ NN414-treated GT1-
KCl þ NN414-treated cells (n ¼ 11e12). (E) Conductance density at run-up for 3-h
an ± SEM. **p < 0.01, ***p < 0.001.
Fig. 5. Tolbutamide prevents chronic NN414-associated attenuation of KATP channel conductance. (A) Representative perforated-patch current clamp recording of a GT1-7 cell
demonstrating that 5 mM NN414 does not hyperpolarize the cell membrane when applied in the presence of 200 mM tolbutamide. Note that addition of tolbutamide causes a small
depolarization as reported previously (Beall et al., 2012). (B, C) Representative whole-cell current-clamp recordings of membrane potential and voltage-clamp recordings of currents
from 24-h vehicle- (B) and 24-h tolbutamide þ NN414-treated GT1-7 cells (C). (D) Pooled conductance density at run-up from 24-h vehicle (white bars; n ¼ 7) vs. 24-hour
tolbutamide þ NN414-treated cells (black bars; n ¼ 5). Values are mean ± SEM.
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ration in symmetrical 140 mM Kþ solutions and assurance of stable
recording conditions, the membrane potential was clamped
at 50 mV. Patches isolated from GT1-7 cells exposed for 24 h to
vehicle-containing solution exhibited typical KATP single channel
activity, which was reversibly inhibited by the application of
100 mMMgATP to the cytoplasmic aspect of the membrane (Fig 6A).
Furthermore, application of 200 mM MgADP to the membrane eli-
cited KATP channel activation (Dunne and Petersen, 1986; Kakei
et al., 1986), and 100 mM NN414, in the presence of 100 mM
MgATP (Dabrowski et al., 2003), induced a large increase in channel
opening (Fig. 6B, C), as expected. In contrast, inside-out patches
excised from GT1-7 cells following 24-h exposure to NN414 were
characterised by the relative absence of channel openings, indi-
cating a substantial reduction in the intrinsic activity of the channel
(Fig. 6B,C top trace), with complete insensitivity to activation by
application of 200 mM MgADP or 100 mM NN414 þ 100 mM MgATP
(Fig. 6B,C). Finally, to ensure antecedent NN414-exposed cell-
derived patches contained channels capable of being activated,
patches were subsequently exposed to trypsin (100 mg/ml), which
has previously been demonstrated to re-activate “run-down” KATP
channels (Lee et al., 1994a; Proks and Ashcroft, 1993). Exposure of
patches to trypsin (2 min) yielded a comparable level of KATP acti-
vation in both treatment groups (NN414: N.Po ¼ 0.265 ± 0.161;
Vehicle: N.Po ¼ 0.318 ± 0.20; Fig. 6B,C).4. Discussion
There is a clear need to develop novel approaches to prevent
hypoglycaemia in individuals with long-term T1D, as current
strategies are relatively ineffective and hypoglycaemia remains the
major limitation to intensive insulin therapy. Studies on rats by
microinjection of the non-selective KATP channel opener, diazoxide
into the VMH (McCrimmon et al., 2005) or by systemic delivery of
the SUR1-selective opener, NN414 (Fan, et al., 2008) demonstrated
promising results with the ampliﬁcation of the CRR to hypo-
glycaemia. Subsequently, ingestion of diazoxide by T1D subjects
under hyperinsulinemic hypoglycaemic clamp demonstrated an
improved CRR, which was diminished in individuals with a KATP
channel polymorphism that is associated with diabetes (George
et al., 2015).
Conversely, we have previously demonstrated that continuous
central NN414 exposure, rather than defending against the devel-
opment of defective CRR in response to repetitive hypoglycaemic
challenge, attenuates the CRR to hypoglycaemia in vivo and reduces
KATP channel conductance density in vitro (Beall et al., 2013). Here
we show that continuous NN414 application for 24 h also blunted
low-glucose sensing in the GT1-7 cell line. Such an effect in vivo
could therefore account for the suppression of the CRR to hypo-
glycaemia following chronic NN414 exposure. Although termina-
tion of NN414 administration in vivo partially restored the CRR
Fig. 6. Chronic NN414 treatment drives KATP channels into an inactive state unresponsive to channel agonists. (A) Representative single channel recording from an isolated inside-
out membrane patch from control GT1-7 cells, recorded in symmetrical 140 mM KCl at a membrane potential of 50 mV. Channel openings (inward current) are represented as
downward deﬂections. The addition of 100 mM MgATP almost completely inhibits channel activity. (B) Representative inside-out single channel recordings from 24-h vehicle-
treated and 24-h NN414-treated GT1-7 cells. This demonstrates that the intrinsic KATP channel activity is higher in vehicle-vs. NN414-treated cells (top trace) and that the acti-
vation induced by addition of 200 mMMgADP (second trace) or 100 mMMgATP þ 100 mM NN414 (third trace) to the cytoplasmic aspect of the membrane observed in 24-h vehicle-
treated cells is absent in the 24-h NN414-treated cells. In contrast, 100 mg/ml trypsin application to the cytosolic domain of the inside-out patches elicited comparable responses
between vehicle- and NN414-treated cells (bottom trace). (C) Bar graph of mean KATP channel activity (N.Po) from inside-out patches obtained from 24-h vehicle- (white bars) and
24-h NN414- (black bars) treated cells (n ¼ 4e11). ## denotes an N.Po value < 0.001. Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
E. Haythorne et al. / Neuropharmacology 111 (2016) 212e222220response to hypoglycaemia and removal of NN414 from GT1-7 cells
recovered whole-cell KATP conductance (Beall et al., 2013), we ﬁnd
that the responsiveness of GT1-7 cells to hypoglycaemic challenge
remains impaired. One plausible explanation we explored was that
chronic exposure to the KATP openers resulted in a “metabolic
adaptation” leading to maintained levels of intracellular ATP under
hypoglycaemic conditions, as has been reported for diazoxide in
islets (Elmi et al., 2000). Thus we examinedwhether chronic NN414
exposure induced adaptations in cellular glucose metabolism or
mitochondrial function in GT1-7 cells. We found no signiﬁcant
changes in glucose uptake, hexokinase activity or glucose oxidation
in normo- or hypoglycaemic conditions nor did we observe any
alteration in the oxygen consumption rate, mitochondrial electron
transfer function or cytosolic ATP:ADP ratio in GT1-7 cells following
chronic NN414 treatment in comparison with vehicle controls. As
such a change in neuronal bioenergetics following KATP activation is
unlikely to explain the persisting defect in glucose sensing.
Consequently, we next focused on the possibility that long-term
exposure to these channel openers resulted in a functional change
in the KATP channel itself, either via prolonged hyperpolarization
(voltage-dependent) per se or by binding of the KATP openers to thechannel protein complex. Using increased extracellular Kþ con-
centration to chemically-clamp the membrane potential to ~ -
50 mV and prevent hyperpolarization by NN414, we demonstrated
that chronic exposure to this channel opener still resulted in
severely attenuated KATP cellular conductance. In contrast, the
presence of a selective KATP inhibitor, the sulphonylurea tolbuta-
mide, which maintained the channel in the closed conformation
prior to and during exposure to NN414, prevented the NN414-
mediated reduction in whole-cell KATP conductance. This outcome
indicates that either the presence of tolbutamide prevents NN414
from binding to the KATP channel or that prolonged opening by the
agonist, allosterically prevented by tolbutamide binding, results in
the channel entering a stable inactivated state. Although the exact
binding site for the KATP openers has not yet been fully established,
the selective agonist activity of NN414 is dependent on intact
Walker A motifs of the nucleotide binding domains of SUR1
(Dabrowski et al., 2003). Furthermore, [3H]-glibenclamide binding
to SUR1 can be displaced by NN414 (Nielsen et al., 2006) and
tolbutamide (Niki et al., 1989) which has been demonstrated to
bind to the COOH terminal group of SUR1 transmembrane domains
(Ashﬁeld et al., 1999) and may also interact with diazoxide at these
E. Haythorne et al. / Neuropharmacology 111 (2016) 212e222 221and additional sites on SUR1 (Babenko et al., 2000).
Nevertheless, regardless of the exact physical interaction site,
prevention of KATP opening protects the channel from entering a
long-lived closed or inactivated state. In an attempt to examine this
further, we assessed single channel activity in excised patches
following chronic NN414 or vehicle exposure of GT1-7 cells. This
revealed a severe loss of channel activity in patches excised from
NN414-treated cells compared to vehicle controls, indicative of
inhibition of the intrinsic gating activity of the channel in the
absence of regulatory nucleotides. Furthermore, KATP opening could
not be elicited by the natural agonist MgADP applied to the intra-
cellular aspect of the patch, in comparison to vehicle-treated
channels, which responded with increased activity as expected
(Dabrowski et al., 2003; Gribble et al., 1997a) or indeed by NN414 in
the presence of MgATP (Dabrowski et al., 2003). The lack of
responsiveness to MgADP is also consistent with the proposition
that chronic NN414 treatment affects the gating capability of the
channel through actions on SUR1 (Gribble et al., 1997b). In an
attempt to demonstrate that functional channels were still present
in excised patches from NN414-treated GT1-7 cells, the protease
trypsin was applied to the intracellular aspect of the membrane.
Previous studies have shown that trypsin re-activates KATP chan-
nels, which have been allowed to undergo the slow inactivation
process termed “run-down” observed in inside-out patches from
pancreatic b-cells (Lee et al., 1994a, 1994b). Indeed, we show that
trypsin treatment re-activates channels in patches from chronic
NN414-treated cells to the same extent as patches from vehicle-
treated cells. This outcome is consistent with our ﬁnding that
chronic NN414 does not affect KATP channel subunit trafﬁcking to
the plasma membrane (Beall et al., 2013). Interestingly, trypsin
treatment of the intracellular aspect of isolated patches severely
reduces the sensitivity of KATP to inhibition by sulphonylureas,
along with complete loss of [3H]-glibenclamide binding (Lee et al.,
1994a). A simple explanation for this outcome is that trypsin
cleaves SUR1 (or at least the portion of SUR1 containing the binding
site for sulphonylureas) from the KATP complex, thus also poten-
tially removing any NN414 still bound to this site. Alternatively,
trypsin treatment cleaves that part of the channel complex
responsible for the sustained conformational change underlying
the inactivated state, as has been described for other types of Kþ
channels (Hoshi et al., 1990; Kirsch and Brown, 1989; Solaro and
Lingle, 1992). An interesting question that arises from these ﬁnd-
ings is whether KCOs induce this effect exclusively on hypothalamic
neurons or it is a generalised action on KATP channels and may be
observable in other tissues such as pancreatic beta cells? Addi-
tionally, to enable detailed examination of the biophysical nature of
the KCO effect similar experiments should be performed on re-
combinant Kir6.2/SUR1 (or other subunit combinations) channels.
Such studies are currently underway.
In conclusion, although short-term application of KATP channel
openers, such as the SUR1-selective opener NN414, appear to have
excellent therapeutic potential for normalising defective CRR, the
results from in vivo rodent work and our in vitro cellular data
strongly suggests theremay be a potential drawbackwith the use of
such an agent given chronically as a preventative therapy. Perhaps
the development of structurally modiﬁed SUR1-selective KATP
openers with lower efﬁcacy or openers that act at a different site on
the channel complex will circumvent this problem. Alternatively,
lower dose NN414 or diazoxide and/or intermittent dosage regimes
could be tested using this neuronal model and rodents in an
attempt to obviate this difﬁculty prior to further trials in humans.
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